Mood Swings, Irregular Periods, Fatigue After 35 — Is This Perimenopause? What Shatavari and Science Say for Indian Women

By Kuerzen Research Team | Kuerzen BioSolutions Pvt. Ltd. | FSSAI Certified

You are 37. Or 41. You sleep eight hours and wake up exhausted. Your periods were like clockwork for twenty years and now they are arriving ten days early, or skipping a month entirely. You feel anxious at moments that would never have bothered you before. Your mood dips without obvious reason and lifts just as unpredictably. You forget words in the middle of sentences. You are managing your career, your family, your household — and you feel, beneath all of it, like your body has quietly started doing something you were never told to expect this early.

Most Indian women in this situation do the same thing: they attribute it to stress, overwork, or simply getting older. They are rarely wrong about the stress. But they are almost always missing a more specific and clinically significant explanation — one that affects the majority of Indian women in their thirties and forties, goes largely undiagnosed, and is entirely manageable when understood correctly.

The explanation is perimenopause. And the science of 2026 — including a landmark international study of over 17,000 women across 158 countries — confirms that many women experiencing clear biological indicators of perimenopause are not being identified as such, leading to delays in care, misclassification, and unnecessary reductions in quality of life. India's situation is particularly striking. By 2030, nearly 130 million Indian women are expected to be in the menopausal phase — yet perimenopause continues to be sidelined in both public health discourse and policy frameworks, with myths and misconceptions prevailing (Talaulikar VS, BJOG, 2026).

________________________________________________________________________________________________

What Is Perimenopause — And Why Is It Happening Earlier Than Most Indian Women Expect

Perimenopause is not menopause. It is the transitional phase that precedes menopause — a period of hormonal fluctuation that can last anywhere from two to eight years, during which oestrogen and progesterone levels do not simply decline but fluctuate unpredictably. Some months feel entirely normal. Others feel completely unfamiliar. This unpredictability is one of the reasons the symptoms can feel so confusing — because they come and go rather than arriving in a steady, recognisable pattern.

The average age of perimenopause onset in Indian women is typically between 40 and 45 — approximately two years earlier than the global average of 47, according to data published in the Indian Journal of Medical Research. However, recent clinical evidence confirms that symptoms can begin well before 40, and a 2026 international study involving over 17,000 women found significant disconnects between the symptoms women recognise as perimenopausal and the symptoms they actually experience — meaning many women in their mid to late thirties are in early perimenopause without knowing it.

What causes this transition is the gradual decline of ovarian follicles — the structures that produce oestrogen and are responsible for ovulation. As follicle reserves diminish, the hormonal signals that regulate the menstrual cycle become less consistent. Oestrogen levels fluctuate rather than decline smoothly, creating the wide range of physical and psychological symptoms that characterise this phase. Because oestrogen interacts with brain chemicals involved in mood, motivation, memory, sleep and emotional regulation — and progesterone influences calming pathways in the brain through its action on GABA receptors — the psychological symptoms of perimenopause are frequently as pronounced as the physical ones. This neuroendocrine interplay explains why cognitive and affective disturbances are not merely "stress-related" but are rooted in measurable changes in brain neurotransmitter systems.

________________________________________________________________________________________________

The Symptoms Most Indian Women Miss — A Complete Picture

A comprehensive study of perimenopausal symptoms in Indian women published in the Indian Journal of Forensic and Community Medicine (2025) found that 87.7% of women had measurable symptoms — yet the majority attributed them to other causes and did not connect them to hormonal transition. Understanding the full spectrum of perimenopause symptoms is the first step toward managing them effectively.

Irregular periods are the most clinically recognised symptom of perimenopause and are often the first to appear. Cycles that were previously regular may become shorter, longer, heavier, lighter, or may skip months entirely. This happens because the hormonal signalling that triggers ovulation becomes less consistent as follicle reserves decline. For Indian women, irregular cycles are frequently dismissed as stress-related or cycle variations — missing the hormonal explanation that would allow for more appropriate management. Clinically, this menstrual irregularity is a key diagnostic marker that should prompt further evaluation.

Mood changes and anxiety are among the most prevalent and underrecognised symptoms in Indian women. The same 2025 Indian study found that anxiety was reported by 80% of perimenopausal participants — making it the highest reported symptom across the cohort. Mood swings — periods of irritability, low motivation, or emotional sensitivity that do not correspond to obvious external triggers — were reported by 60.7% of participants. These are not signs of psychological weakness. They are direct consequences of oestrogen and progesterone fluctuation acting on the brain's neurotransmitter systems, particularly serotonin, dopamine, and norepinephrine. The amygdala and prefrontal cortex, which regulate emotional processing and executive function, are rich in oestrogen receptors, making them highly susceptible to hormonal volatility.

Fatigue and physical exhaustion affected 71.5% of Indian women in the same cohort — not the ordinary tiredness of a demanding lifestyle but a deeper, more persistent depletion that sleep does not fully resolve. This fatigue has multiple simultaneous causes in perimenopause: disrupted sleep from night sweats and hormonal fluctuation, reduced iron stores from heavy perimenopausal cycles, and the metabolic impact of oestrogen decline on cellular energy production, including mitochondrial dysfunction and reduced ATP synthesis. The cumulative effect of these factors creates a profound state of energy deficit that standard lifestyle modifications alone cannot address.

Brain fog and cognitive changes are one of the most frightening and least discussed perimenopause symptoms in India. Women in perimenopause may forget names, lose words mid-sentence, feel slower than usual, or find that their characteristic sharpness and ability to manage multiple demands simultaneously has become effortful. A 2025 quality-of-life study of 387 perimenopausal women found that anxiety symptoms were present in 58.9% and depressive symptoms in 68.7% — and cognitive difficulty was significantly associated with both (Liu et al., Archives of Gynaecology and Obstetrics, 2025). For Indian women used to managing families, teams, deadlines and decisions simultaneously, this cognitive shift can feel deeply unsettling. Neuroimaging studies have shown that oestrogen influences hippocampal function and synaptic plasticity, explaining why memory and verbal fluency are particularly affected during this transition.

Hot flashes and sleep disturbances, while most commonly associated with menopause, frequently begin in perimenopause. A 2025 clinical study confirmed that vasomotor symptoms — hot flashes and night sweats — and vaginal dryness clearly differentiate perimenopause from premenopause, supporting their use as early diagnostic markers. These vasomotor symptoms are driven by oestrogen withdrawal affecting the thermoregulatory centre in the hypothalamus, leading to inappropriate peripheral vasodilation and heat dissipation responses.

Joint and muscular discomfort were reported by 56% of Indian women in the 2025 study — a symptom rarely connected to hormonal transition but directly related to declining oestrogen's effect on joint lubrication and collagen maintenance in connective tissue. Oestrogen receptors are present in synovial tissues, and oestrogen decline is associated with increased inflammatory markers such as interleukin-6 and tumour necrosis factor-alpha, which contribute to arthralgia and myalgia.

The customer truth: If you are in your late thirties or forties and recognise three or more of these symptoms occurring simultaneously without a clear alternative explanation, perimenopause is a clinically credible explanation that warrants attention — and one that is rarely offered proactively in Indian healthcare settings.

________________________________________________________________________________________________

Why Indian Women Face Perimenopause Differently

The Indian context adds specific layers of complexity to perimenopause that are distinct from the global average and that most available guidance — much of it produced for Western populations — does not adequately address.

Indian women enter perimenopause approximately two years earlier than the global average — a difference associated with several population-specific factors. Widespread nutritional deficiencies — iron, Vitamin D, Vitamin B12, and protein — accelerate the metabolic and inflammatory processes that drive hormonal dysregulation. Urban sedentary lifestyles and chronic psychological stress from managing careers, households, childcare, and extended family responsibilities elevate cortisol, which directly disrupts progesterone production and accelerates follicular decline. Lower average body mass than Western populations means that Indian women have less peripheral oestrogen conversion from adipose tissue — reducing the natural hormonal buffer during the transition. This lower peripheral conversion of androstenedione to oestrone means that Indian women may experience more pronounced symptoms at comparable oestrogen decline levels.

Beyond the biological factors, Indian women face significant cultural barriers to recognising and addressing perimenopause. A 2026 BJOG study specifically examining menopause transition in India found that myths and misconceptions prevail — including the widespread belief that hormonal changes begin abruptly at a later age — and that women experiencing clear perimenopausal symptoms are frequently not offered appropriate clinical guidance. The same study noted that by 2030, nearly 130 million Indian women will be in the menopausal phase — a public health challenge of enormous scale that remains largely unaddressed. Additionally, the tendency to normalise symptoms as "part of being a woman" or "just aging" further delays help-seeking behaviour and appropriate intervention.

________________________________________________________________________________________________

What Shatavari Does for Perimenopause — The Clinical Evidence

Shatavari (Asparagus racemosus) has been used in Ayurvedic medicine for over three thousand years as the foundational herb for women's reproductive and hormonal health across all life stages — from menarche through menopause. Its Sanskrit name translates to "she who possesses a hundred husbands" — a reference to its traditional role in sustaining female vitality and reproductive resilience throughout life. What makes Shatavari particularly relevant to perimenopause in 2026 is the growing body of clinical evidence confirming specific mechanisms of action on the precise biological pathways that perimenopause disrupts.

Shatavari's active compounds — called shatavarins — are steroidal saponins with phytoestrogenic properties. Phytoestrogens are plant-derived compounds that bind to oestrogen receptors and exert mild oestrogenic effects — providing a degree of oestrogen-like activity that can help moderate the impact of declining endogenous oestrogen without the risks associated with synthetic hormone replacement therapy. A pilot human trial published in the Journal of Ayurveda and Integrative Medicine found that Shatavari supplementation improved menopausal symptoms in 72% of participating women over a 12-week study period — with particular improvements in hot flashes, mood stability, sleep quality, and energy levels. These improvements were measured using validated menopausal rating scales, demonstrating statistically significant reductions in symptom severity scores.

A 2026 review examining perimenopausal symptoms through the lens of Ayurveda, published in the Journal of Ayurveda and Integrated Medical Sciences (Shubhangi and Jaiswal, 2026), confirmed that Shatavari's phytoestrogen content supports the hypothalamic-pituitary-ovarian axis during transition — promoting more regular hormonal signalling, supporting oestrogen receptor activity in the absence of adequate endogenous oestrogen, and modulating the inflammatory processes that contribute to hot flashes and mood instability. Crucially, Shatavari's mechanism is regulatory rather than additive — it does not introduce exogenous hormones but supports the body's own hormonal signalling system during a period of transition. This adaptogenic-regulatory profile makes it particularly suitable for the fluctuating hormonal environment of perimenopause, as opposed to the more stable post-menopausal phase.

For the specific cognitive symptoms of perimenopause — brain fog, memory difficulty, word retrieval issues — Shatavari's adaptogenic properties are relevant. As an adaptogen, it helps the body maintain homeostasis under physiological stress. Given that cognitive symptoms in perimenopause are directly related to hormonal fluctuation acting on brain neurotransmitter systems, an ingredient that moderates hormonal variability addresses the root cause of these cognitive changes rather than treating symptoms in isolation. Furthermore, Shatavari has demonstrated neuroprotective effects in preclinical studies, including antioxidant activity and modulation of acetylcholinesterase, which may contribute to its cognitive benefits.

The customer truth: Shatavari is not simply a menopause supplement. It is a regulatory botanical that supports the hormonal communication system that perimenopause disrupts — and the clinical evidence for its relevance to this transition is now well-established in both traditional and modern medical literature. When standardised to a clinically meaningful shatavarin content, it represents one of the most evidence-backed botanical interventions for this life stage.

________________________________________________________________________________________________

What Ashwagandha Adds — The Cortisol and Resilience Layer

The stress-hormone connection in perimenopause is significant and rarely addressed by conventional guidance. Cortisol — the primary stress hormone produced by the adrenal glands — rises during perimenopause as the body attempts to compensate for declining ovarian hormone production. Elevated cortisol directly suppresses progesterone synthesis, worsens anxiety and sleep disruption, promotes abdominal fat accumulation, and accelerates the follicular decline that drives perimenopause forward. This phenomenon is often referred to as the "pregnenolone steal" or "cortisol steal" hypothesis, where the adrenal glands prioritise cortisol production over progesterone synthesis under chronic stress.

Ashwagandha (Withania somnifera) KSM-66 — the clinically validated full-spectrum root extract — directly targets this cortisol pathway. A landmark randomised controlled trial published in the Indian Journal of Psychological Medicine (Chandrasekhar et al., 2012) demonstrated a 27.9% reduction in serum cortisol following eight weeks of KSM-66 supplementation alongside significant improvements in self-reported stress, anxiety, and quality of life. In the perimenopause context, reducing cortisol does not merely alleviate stress symptoms — it removes one of the primary biological factors accelerating hormonal disruption. By lowering cortisol, Ashwagandha indirectly supports progesterone production and restores a more favourable oestrogen-to-progesterone ratio.

The combination of Shatavari and Ashwagandha addresses perimenopause at two distinct but complementary levels: Shatavari supporting the oestrogen receptor pathway and hormonal regulation from the reproductive axis, Ashwagandha reducing the cortisol-driven disruption from the adrenal axis. Together, they represent the most evidence-supported dual-adaptogen approach to perimenopausal symptom management available in the natural supplementation space. This synergistic mechanism is particularly relevant for Indian women, who face high chronic stress loads and early perimenopause onset, making adrenal support as important as ovarian support.

________________________________________________________________________________________________

Why Iron and Protein Matter More During Perimenopause Than Most Women Realise

The nutritional needs of perimenopausal Indian women are significantly different from the nutritional needs of younger women — and most supplement advice fails to account for this.

Heavy or irregular perimenopausal cycles deplete iron stores substantially over months and years. Iron deficiency — already affecting over 50% of Indian women (NFHS-5, 2019-21) — worsens significantly during perimenopause, compounding the fatigue and cognitive difficulty that hormonal changes are already producing. Without adequate iron, haemoglobin production is impaired, reducing oxygen delivery to every tissue in the body — including the brain. For Indian women experiencing perimenopause-related brain fog and fatigue, iron deficiency is frequently a concurrent and significantly amplifying factor. Serum ferritin levels below 30 ng/mL indicate absolute iron deficiency, yet many women in this phase have levels substantially lower without being tested or supplemented.

Protein deficiency — affecting over 73% of Indians per IMRB data — creates an additional burden during perimenopause. Protein is required for the production of neurotransmitters including serotonin and dopamine — the mood-regulating chemicals that oestrogen decline directly impairs. Adequate protein intake supports muscle mass maintenance at a time when declining oestrogen reduces anabolic efficiency. It supports collagen production at a time when skin, joint, and connective tissue changes are accelerating. And it provides the amino acid building blocks for the adrenal hormones whose balance becomes critically important as ovarian hormone production declines. Specifically, tryptophan is a precursor to serotonin, tyrosine is a precursor to dopamine and norepinephrine, and glutamine supports GABA synthesis — all of which are directly impacted by oestrogen decline.

The combination of hormonal transition, iron depletion from irregular cycles, protein deficiency from typical Indian diets, and the extraordinary physical and psychological demands placed on Indian women in their thirties and forties creates a nutritional context that standard supplement advice — designed for younger, generally healthier, often Western populations — simply does not address. A comprehensive nutritional strategy must therefore include bioavailable iron, complete protein sources, and co-factors such as Vitamin C and B-vitamins to support energy metabolism and neurotransmitter synthesis.

________________________________________________________________________________________________

What Can Help?

For Indian women navigating perimenopause and seeking daily nutritional support that addresses this transition from multiple angles simultaneously, Kuerzen's Super Her is formulated with precisely this life stage in mind. Super Her delivers Shatavari and Ashwagandha KSM-66 — both at clinically meaningful doses — alongside Spirulina for iron absorption support (with Vitamin C for 300% enhanced absorption), Flaxseed lignans for oestrogen metabolism support, plant-based protein from pea and brown rice for neurotransmitter support and muscle maintenance, and digestive enzymes to ensure optimal nutrient uptake at a time when digestive efficiency also typically declines.

Every ingredient in Super Her has a specific, evidence-based role in the nutritional management of perimenopause — not as a treatment for any medical condition, but as comprehensive daily nutritional support for the biological transitions that perimenopause represents. Super Her is FSSAI-certified, GMP-manufactured at Kuerzen Biosolutions Pvt. Ltd. in Greater Noida, and developed by a pharmaceutical team with over 20 years of clinical research experience. The formulation is designed to address the multi-system nature of perimenopause — neuroendocrine, adrenal, metabolic, and nutritional — in a single, convenient daily intervention.

________________________________________________________________________________________________

Frequently Asked Questions

What age does perimenopause start for Indian women?

While the global average age for perimenopause onset is approximately 47, Indian women typically begin the transition two years earlier — between 40 and 45 — with some experiencing early perimenopausal symptoms in their mid to late thirties. A 2026 international study of over 17,000 women confirmed that many women do not realise symptoms can begin in their 30s, leading to significant delays in recognition and appropriate management. If you are over 35 and experiencing a cluster of the symptoms described above — particularly irregular cycles alongside mood changes and fatigue — perimenopause is a clinically credible explanation that warrants discussion with a healthcare professional. Early recognition and intervention can significantly improve quality of life and reduce symptom severity.

Are mood swings and anxiety a normal part of perimenopause?

Yes — and significantly so in Indian women. A 2025 Indian study found that anxiety was the most prevalent perimenopausal symptom, affecting 80% of participants, while mood changes and irritability affected over 60%. These are not psychological symptoms in the sense of being personality-based or stress-induced in the conventional sense — they are direct neurological consequences of oestrogen and progesterone fluctuation acting on the brain's mood regulation systems. Recognising this distinction is important because it changes the management approach from purely psychological interventions to ones that also address the underlying hormonal drivers. The brain has a high density of oestrogen receptors in regions responsible for emotional regulation, including the amygdala, hippocampus, and prefrontal cortex, making hormonal fluctuations a primary driver of mood changes.

Can Shatavari help with perimenopause symptoms?

Clinical evidence supports the use of standardised Shatavari in the context of perimenopausal symptom management. A human pilot trial found improvements in menopausal symptoms in 72% of participants over 12 weeks, with particular benefits for mood stability, hot flashes, sleep quality, and energy. A 2026 Ayurvedic clinical review confirmed Shatavari's phytoestrogenic mechanism is specifically relevant to the oestrogen receptor pathway disrupted by perimenopause. Shatavari is not a treatment for perimenopause and does not replace medical consultation — but at a clinically meaningful standardised dose, the evidence for its supportive role in this transition is well-established. The shatavarin content and standardisation of the extract are critical determinants of its clinical efficacy.

Is brain fog during perimenopause permanent?

Brain fog during perimenopause is typically not permanent. It is directly related to hormonal fluctuation, sleep disruption, iron deficiency, and psychological stress — all of which are partially or fully addressable. A 2025 quality-of-life study of perimenopausal women found that cognitive symptoms were significantly associated with anxiety, depression, and poor sleep — all of which respond to both lifestyle interventions and appropriate nutritional support. Women who address the underlying drivers — hormonal support, iron repletion, sleep improvement, stress reduction — typically report significant improvement in cognitive clarity over an 8 to 12 week period. The hippocampus, a brain region critical for memory formation, is highly sensitive to oestrogen, and its function typically improves as hormonal balance is restored.

What is the difference between perimenopause and menopause?

Perimenopause is the transitional phase preceding menopause — a period of hormonal fluctuation that can last two to eight years, during which menstruation continues but becomes irregular. Menopause is defined as the point at which 12 consecutive months have passed without a menstrual period. In India, menopause occurs on average around age 46-47 — earlier than the global average. The symptoms experienced during perimenopause — mood changes, irregular cycles, hot flashes, fatigue, brain fog — are a result of fluctuating rather than absent hormones, which is why they can be unpredictable and confusing compared to the more consistent symptom profile of post-menopause. This fluctuation also explains why hormone levels are not consistently low and may appear "normal" on a single blood test, making clinical history a more reliable diagnostic tool.

Does nutrition affect perimenopause symptoms?

Significantly. Nutritional status is one of the most modifiable factors influencing perimenopause symptom severity. Iron deficiency amplifies fatigue and cognitive symptoms. Protein deficiency impairs neurotransmitter production, worsening mood changes. Vitamin D deficiency — affecting over 70% of urban Indian adults — is independently associated with increased hot flash severity and mood disturbance in perimenopause. Adequate intake of phytoestrogen-rich foods and botanicals supports oestrogen receptor activity during the transition. For Indian women, whose nutritional profiles typically show multiple simultaneous deficiencies, addressing nutritional gaps is a high-impact, low-risk first intervention in perimenopause management. Omega-3 fatty acids, B-vitamins, and magnesium also play important roles in mood regulation and neurological function during this phase.

The Bottom Line

Perimenopause is not something that happens to older women. For millions of Indian women in their thirties and forties, it is happening right now — quietly, without explanation, and without adequate medical recognition or cultural conversation. The mood swings that feel like stress. The irregular cycles that seem like a phase. The fatigue that sleep does not fix. The brain fog that makes you question your own sharpness. These are not personal failings or inevitable features of being a busy Indian woman. They are biological signals of a hormonal transition that begins earlier in India than most women are ever told.

Understanding perimenopause — and addressing it with the right combination of adaptogenic botanical support, targeted nutrition, and adequate protein and iron — changes the experience of this transition fundamentally. The science of 2026 is clear on what helps. Three thousand years of Ayurvedic clinical observation got there first. The convergence of traditional wisdom and modern clinical evidence provides a robust framework for managing this life stage effectively, restoring vitality, and maintaining quality of life through a carefully designed nutritional and lifestyle strategy.

For more information, visit kuerzen.com

_______________________________________________________________________________________________

Key References

[1] Talaulikar VS. Optimising Clinical Support and Access to Information on Menopause Transition in India. BJOG. 2026. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.70272

[2] Perimenopause in 2026: why new global research calls for updated diagnostic criteria and improved symptom recognition. SFI Health. 2026. https://sfihealth.com/news/perimenopause-in-2026-why-new-global-research-calls-for-updated-diagnostic-criteria-and-improved-symptom-recognition

[3] Prevalence of menopausal symptoms in Indian women. Indian Journal of Forensic and Community Medicine. 2025;12(1):40-44. https://ijfcm.org/archive/volume/12/issue/1/article/14735/pdf

[4] Liu X et al. Investigation of the quality of life and influencing factors among perimenopausal women. Archives of Gynaecology and Obstetrics. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414071/

[5] Shubhangi, Jaiswal R. Reviewing Perimenopausal Symptoms Through the Lens of Ayurveda. Journal of Ayurveda and Integrated Medical Sciences. 2026. https://jaims.in/jaims/article/view/5490

[6] Chandrasekhar K et al. A prospective, randomised double-blind study of Ashwagandha root extract on stress and anxiety. Indian Journal of Psychological Medicine. 2012. https://pubmed.ncbi.nlm.nih.gov/23439798/

[7] Choudhury et al. Effectiveness of Multisymptom Support for Better Relief and Alleviation of Common Effects in Perimenopause. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12267593/

[8] NFHS-5. National Family Health Survey India 2019-21. http://rchiips.org/nfhs/NFHS-5Reports/NFHS-5_INDIA_REPORT.pdf

[9] Perimenopause in Indian Women: Mental Health Symptoms. Miror. 2026. https://miror.in/perimenopause-in-indian-women-mental-health/